United States: The Federal Circuit Clarifies The Steps In The Biosimilars Dance

Last Updated: July 28 2015
Article by Ping Wang, M.D. and John Murray

On July 21, 2015, in Amgen Inc. v. Sandoz Inc., No. 15-1499, (Fed. Cir. July 21, 2015), the U.S. Court of Appeals for the Federal Circuit issued a long-anticipated decision concerning the necessity and timing of certain disclosures by companies seeking an FDA license to market a biosimilar drug. In short, the split decision holds that (a) the so-called "patent dance," i.e., the disclosure of the biosimilar application and identification of patents, is not mandatory, and (b) the biosimilar applicant's notice of commercial marketing cannot be made until FDA actually grants a license for the biosimilar product. The decision is a partial victory for Amgen, providing a 180-day extension of its exclusivity period for its product Neupogen®, but it is also a significant victory for biosimilar applicants who hope to delay disclosure of their biosimilar applications and manufacturing information. Of course, the parties will likely seek rehearing en banc, so the legal issues are far from settled.

The Biologics Price Competition and Innovation Act of 2009 (BPCIA)

Congress enacted the BPCIA to address concerns about a perceived lack of competition in the biologics drugs market. The BPCIA includes three major elements. First, the BPCIA establishes a pathway for submitting an abbreviated biologics license application (aBLA) for approval of competing versions of previously marketed biologics. Specifically, the BPCIA regulates follow-on biologics, or "biosimilars." The Food and Drug Administration (FDA) plays a central role in determining the particular standards for establishing "biosimilarity" and "interchangeability" for individual products. Second, the BPCIA allows FDA-administered periods of regulatory exclusivity for certain brand name drugs and follow-on products. The BPCIA also creates a term of regulatory exclusivity for the applicant that is the first to demonstrate that its product is interchangeable with the brand name product. Finally, the BPCIA creates a distinct patent dispute resolution procedure for use by brand name and follow-on biologic manufacturers.

The Patent Dance Is Not Mandatory Because "Shall" Means "May"

The Federal Circuit first addressed the question of whether a biosimilar applicant is required to disclose its aBLA and manufacturing information in accordance with 42 U.S.C. § (l)(2)(A). The majority (Lourie and Chen) concluded that it was not, despite the use of "shall," while Judge Newman dissented.

The applicable provision states that "the subsection (k) applicant shall provide to the reference product sponsor a copy of the application submitted to the Secretary under subsection (k), and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application." 42 U.S.C. § (l)(2)(A). The majority concluded that "shall," when "read in isolation," requires mandatory disclosure by the stated deadline. But other sections of the BPCIA gave context that the disclosure was not mandatory. Under 42 U.S.C. § 262(l)(9)(C) and 35 U.S.C. § 271(e)(2)(C)(ii), if the biosimilar applicant fails to make the disclosure, the Reference Product Sponsor (RPS) may bring a declaratory judgment infringement action. Thus, the fallback option expressly contemplated a scenario in which the biosimilar applicant would not make the disclosure under § (l)(2)(A). Under the majority's view, "mandating compliance with paragraph (l)(2)(A) in all circumstances would render paragraph (l)(9)(C) and 35 U.S.C. § 271(e)(2)(C)(ii) superfluous" and thus incorrect1

In dissent, Judge Newman wrote that "[t]his designated exchange of information is fundamental to the BPCIA purposes of efficient resolution of patent issues."2 Judge Newman also took issue with the majority's footnote suggesting that an RPS could assert a process patent in a declaratory judgment action brought pursuant to 42 U.S.C. § 262(l)(9)(C) and 35 U.S.C. § 271(e)(2)(C)(ii).

This ruling has important implications and will affect strategic decisions for biosimilar applicants and reference product sponsors. A company will have to decide whether resolution of the biosimilar patent issues is best resolved through the "patent dance" process established by the BPCIA or through traditional district court litigation via a declaratory judgment action. Moreover, the possibility of asserting process patents in the declaratory judgment action may be a significant factor in deciding which route to choose.

The Marketing Notification Cannot Be Made Until FDA Approves the aBLA, But the Notification is Mandatory Because "Shall" Means "Shall"

The second main issue concerned the marketing notification requirement set forth at 42 U.S.C. § 262(l)(8)(A). Under this provision, the biosimilar applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)." Here, the question was whether Sandoz's early notice—provided before the FDA approved a license for Sandoz's biosimilar product—satisfied the mandate. The majority held that early notification did not count. Thus, under the majority's ruling, the reference product sponsor will have an extra 180 days of exclusivity.

The majority (this time, Lourie and Newman) agreed with Amgen's argument that the provision's use of the term "licensed" meant that the product must have already received a license, and not merely a product for which an application was pending.

We agree with Amgen that, under paragraph (l)(8)(A), a subsection (k) applicant may only give effective notice of commercial marketing after the FDA has licensed its product. The statutory language compels such an interpretation. It means that notice, to be effective under this statute, must be given only after the product is licensed by the FDA3

The majority recognized that other sections of the BPCIA distinguished between "biological product licensed under subsection (k)" and "the biological product that is the subject of" an application. The court also concluded that "Congress intended the notice to follow licensure, at which time the product, its therapeutic uses, and its manufacturing processes are fixed."4

In this case, Sandoz had provided its initial notice of marketing in July 2014, the day after FDA accepted Sandoz's aBLA application for review. That notice, under the court's holding, was "premature and ineffective." Sandoz also provided a "further" notice of commercial marketing on March 6, 2015, the day the FDA approved Sandoz's aBLA. The court held that this second notice was "operative and effective." Thus, Sandoz may not market its product until September 2, 2015.

As with § 262(l)(2)(A), supra, the provision for the marketing notice uses the word "shall." But with the marketing notice provision, the court viewed "shall" to be mandatory because it did "not find any provision in the BPCIA that contemplates, or specifies the consequence for, noncompliance with paragraph (l)(8)(A) here, which would be the case if Sandoz attempts to launch in disregard of the requirement of paragraph (l)(8)(A)."5

The court concluded that "Paragraph (l)(8)(A) is a standalone notice provision in subsection (l)," relying in part on Sandoz's concession at oral argument.6 The court therefore held "that, where, as here, a subsection (k) applicant completely fails to provide its aBLA and the required manufacturing information to the RPS by the statutory deadline, the requirement of paragraph (l)(8)(A) is mandatory."7

Judge Chen dissented on the notice requirement issue. Chen concluded that when the biosimilar applicant "fails to comply with (l)(2), the provisions in (l)(3)-(l)(8) cease to matter." Chen criticized the majority, asserting that it created an "extra-statutory exclusivity windfall" having "no basis in the statutory language."8


1 Amgen, slip op. at 14.

2 Id. at 31.

3 Id. at 16.

4 Id. at 17.

5 Id. at 19.

6 Id. at 20.

7 Id. at 21.

8 Id. at 37, 44.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions